ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDocetaxel (DTX) causes skin toxicities despite dexamethasone-based supportive care, and no established adjunctive primary prophylaxis exists. We assessed whether desloratadine, a peripheral H1-receptor antagonist with anti-inflammatory properties, was associated with DTX-related skin toxicities in early-stage breast cancer.
methodsThis single-center retrospective cohort included 143 patients with stage I-III breast cancer receiving perioperative DTX-based chemotherapy (75 mg/m
resultsAfter stabilized IPTW, skin-toxicity incidence was 46.2% with desloratadine and 70.7% without it (risk difference, - 24.6 percentage points; 95% CI, - 43.0 to - 5.3; risk ratio [RR], 0.65; 95% CI, 0.42-0.92). Descriptive estimates indicated lower pruritus incidence (RR, 0.36; 95% CI, 0.08-0.79), a lower but imprecise rash estimate (RR, 0.70; 95% CI, 0.43-1.03), and no lower HFS incidence (5.9% vs 5.4%). Post-implementation findings were similar (RR, 0.61; 95% CI, 0.42-0.90); negative-control neuropathy was not lower (RR, 1.19; 95% CI, 0.52-2.58).
conclusionDesloratadine prophylaxis was associated with lower skin-toxicity risk, particularly for pruritus. Rash risk was lower but imprecisely estimated; HFS risk was not lower. These hypothesis-generating findings warrant validation in a prospective randomized trial.
Indexed as
Identifiers
42895563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.